Very late vasomotor responses and gene expression with bioresorbable scaffolds and metallic drug‐eluting stents

To investigate the long‐term vasomotor response and inflammatory changes in Absorb bioresorbable vascular scaffold (BVS) and metallic drug‐eluting stent (DES) implanted artery.

[1]  P. Serruys,et al.  Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up: A Systematic Meta-analysis and Individual Patient Data Pooled Study. , 2019, JAMA cardiology.

[2]  P. Ghezzi,et al.  Association between inflammatory biomarkers and neointimal response following elective implantation of the ABSORB bioresorbable vascular scaffold , 2019, Coronary artery disease.

[3]  Dongping Chen,et al.  Effect of inflammation on endothelial cells induced by poly-L-lactic acid degradation in vitro and in vivo , 2018, Journal of biomaterials science. Polymer edition.

[4]  G. Stone,et al.  Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial , 2018, The Lancet.

[5]  Michael C. McDaniel,et al.  Low Coronary Wall Shear Stress Is Associated With Severe Endothelial Dysfunction in Patients With Nonobstructive Coronary Artery Disease. , 2018, JACC. Cardiovascular interventions.

[6]  Si‐Hyuck Kang,et al.  Long-term safety of bioresorbable scaffolds: insights from a network meta-analysis including 91 trials. , 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[7]  P. Teirstein,et al.  3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial. , 2017, Journal of the American College of Cardiology.

[8]  L. Räber,et al.  Mechanisms of Very Late Bioresorbable Scaffold Thrombosis: The INVEST Registry. , 2017, Journal of the American College of Cardiology.

[9]  P. Serruys,et al.  Effect of Technique on Outcomes Following Bioresorbable Vascular Scaffold Implantation: Analysis From the ABSORB Trials. , 2017, Journal of the American College of Cardiology.

[10]  Erhan Tenekecioglu,et al.  Bioresorbable Scaffold: The Emerging Reality and Future Directions , 2017, Circulation research.

[11]  Bernard Chevalier,et al.  Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial , 2016, The Lancet.

[12]  A. Quyyumi,et al.  Vasomotor Function Comparative Assessment at 1 and 2 Years Following Implantation of the Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold and the Xience V Everolimus-Eluting Metallic Stent in Porcine Coronary Arteries: Insights From In Vivo Angiography, Ex Vivo Assessment, and Gene Analysis , 2016, JACC. Cardiovascular interventions.

[13]  W. Cheong,et al.  1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis , 2016, The Lancet.

[14]  Alberto Avolio,et al.  Mechanical stretch: physiological and pathological implications for human vascular endothelial cells , 2015, Vascular cell.

[15]  Habib Samady,et al.  Computational fluid dynamics applied to virtually deployed drug-eluting coronary bioresorbable scaffolds: Clinical translations derived from a proof-of-concept , 2014, Global cardiology science & practice.

[16]  H. Jo,et al.  Flow-dependent regulation of genome-wide mRNA and microRNA expression in endothelial cells in vivo , 2014, Scientific Data.

[17]  Michael C. McDaniel,et al.  Novel drug-eluting stents for coronary revascularization. , 2014, Trends in cardiovascular medicine.

[18]  R. Virmani,et al.  Long-Term Safety of an Everolimus-Eluting Bioresorbable Vascular Scaffold and the Cobalt-Chromium XIENCE V Stent in a Porcine Coronary Artery Model , 2014, Circulation. Cardiovascular interventions.

[19]  Andreas Krämer,et al.  Causal analysis approaches in Ingenuity Pathway Analysis , 2013, Bioinform..

[20]  P. Libby.  Inflammation in Atherosclerosis , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[21]  P. Rigault,et al.  Development of a porcine (Sus scofa) embryo-specific microarray: array annotation and validation , 2012, BMC Genomics.

[22]  R. Whitbourn,et al.  Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trial. , 2012, JACC. Cardiovascular interventions.

[23]  Patrick W Serruys,et al.  Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy? , 2012, European heart journal.

[24]  Masataka Nakano,et al.  The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. , 2011, Journal of the American College of Cardiology.

[25]  J. Visvader,et al.  Discovery of novel mechanosensitive genes in vivo using mouse carotid artery endothelium exposed to disturbed flow. , 2010, Blood.

[26]  D. Holmes,et al.  Segmental coronary endothelial dysfunction in patients with minimal atherosclerosis is associated with necrotic core plaques , 2009, Heart.

[27]  T. Ueland,et al.  Chemokines and Cardiovascular Risk , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[28]  Elena Galkina,et al.  Vascular adhesion molecules in atherosclerosis. , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[29]  U. Ikeda,et al.  Inflammatory cytokines and cardiovascular disease. , 2003, Current drug targets. Inflammation and allergy.

[30]  M. Nakanishi,et al.  Stretch-induced IL-6 secretion from endothelial cells requires NF-κB activation , 2003 .

[31]  R. Terkeltaub,et al.  Chemokines and atherosclerosis. , 1998, Current opinion in lipidology.

[32]  A. Takeshita,et al.  Bradykinin-induced vasodilation of human coronary arteries in vivo: role of nitric oxide and angiotensin-converting enzyme. , 1997, Journal of the American College of Cardiology.

[33]  Carl F. Ware,et al.  Lymphotoxin β, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface , 1993, Cell.

[34]  T. Gräser,et al.  Absence of role of endothelium in the response of isolated porcine coronary arteries to acetylcholine. , 1986, Cardiovascular research.

[35]  T. Nikolskaya,et al.  Functional Analysis of OMICs Data and Small Molecule Compounds in an Integrated "Knowledge-Based" Platform. , 2017, Methods in molecular biology.